SPOCD1 and colorectal carcinoma: The findings highlighted the positive link between SPOCD1 and the sensitivity of anti-tumor drugs such as Bleomycin [32], Cabozantinib [33], Cediranib [34], etc., highlighting that CRC patients with elevated SPOCD1 levels may respond to these medications and suggesting SPOCD1 may be utilized as a predictive marker of the curative efficacy, which is useful for attaining appropriate treatment of CRC.